Efficiency and safety of prolonged levosimendan infusion in patients with acute heart failure

Cardiology Research and Practice

Volumn 1, Issue 1, 2011, Pages

  Aidonidis, Georgios ^a,b   Kanonidis, Ioannis ^b   Koutsimanis, Vasileios ^b   Neumann, Till ^a   Erbel, Raimund ^a   Sakadamis, Georgios ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; LEVOSIMENDAN;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

EID: 79959449589     PISSN: None     EISSN: 20900597     Source Type: Journal    
DOI: 10.4061/2011/342302     Document Type: Article

References (21)

1. Lehmann A., Boldt J., Kirchner J., The role of Ca++-sensitizers for the treatment of heart failure Current Opinion in Critical Care 2003 9 5 337 344 (Pubitemid 37204787)
2. Nieminen M. S., Akkila J., Hasenfuss G., Kleber F. X., Lehtonen L. A., Mitrovic V., Nyquist O., Remme W. J., Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure Journal of the American College of Cardiology 2000 36 6 1903 1912
3. Takahashi R., Talukder M. A. H., Endoh M., Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium European Journal of Pharmacology 2000 400 1 103 112 (Pubitemid 30412115)
4. Sharma M., Teerlink J. R., A rational approach for the treatment of acute heart failure: current strategies and future options Current Opinion in Cardiology 2004 19 3 254 263 (Pubitemid 38657446)
5. Packer M., REVIVE II. MetanalysisSelected adverse events. American Heart Association. Scientific Sessions, 2005
6. Nohria A., Tsang S. W., Fang J. C., Lewis E. F., Jarcho J. A., Mudge G. H., Stevenson L. W., Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure Journal of the American College of Cardiology 2003 41 10 1797 1804 (Pubitemid 36584255)
7. Gegenhuber A., Mueller T., Firlinger F., Lenz K., Poelz W., Haltmayer M., Time course of B-type natriuretic peptide (BNP) and N-terminal ProBNP changes in patients with decompensated heart failure Clinical Chemistry 2004 50 2 454 456 (Pubitemid 38156394)
8. Mavrogeni S., Giamouzis G., Papadopoulou E., Thomopoulou S., Dritsas A., Athanasopoulos G., Adreanides E., Vassiliadis I., Spargias K., Panagiotakos D., Cokkinos D. V., A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure Journal of Cardiac Failure 2007 13 7 556 559 (Pubitemid 47362748)
9. Pder P., Eha J., Sundberg S., Antila S., Heinpalu M., Loogna I., Planken.., Rantanen S., Lehtonen L., Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study Journal of Clinical Pharmacology 2004 44 10 1143 1150 (Pubitemid 39206318)
10. Maisel A. S., The diagnosis of acute congestive heart failure: role of BNP measurements Heart Failure Reviews 2003 8 4 327 334 (Pubitemid 37548051)
11. Giamouzis G., Giannakoulas G., Tsarpalis K., Agha S. A., Georgiopoulou V., Kalogeropoulos A., Karvounis H., Butler J., Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach International Journal of Cardiology 2008 128 1 91 93
12. Arruda P., Long term effect of levosimendan upon BNP levels in patients with decompensated heart failure Critical Care Medicine 2004 32 12, supplement
13. Gianakoulas G., Giannoglou G., Vassilikos V., Clinical significance of acute neorohormonal respons after levosimendan treatment American Journal of Cardiology 2006 98 1123 1124 (Pubitemid 44486130)
14. Nieminen M. S., Bhm M., Cowie M. R., Drexler H., Filippatos G. S., Jondeau G., Hasin Y., Lopez-Sendon J., Mebazaa A., Metra M., Rhodes A., Swedberg K., Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology European Heart Journal 2005 26 4 384 416 (Pubitemid 40283098)
15. American College of Cardiology Expert Consensus Document, Signal- averaged Electrocardiography Journal of the American College of Cardiology 1996 27 1 238 249
16. Provan D., Krentz A., Oxford Handbook of Clinical and Laboratory Investigation 2003 Oxford, UK Oxford University Press
17. Toivonen L., Viitasalo M., Sundberg S., Akkila J., Lehtonen L., Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function Journal of Cardiovascular Pharmacology 2000 35 4 664 669 (Pubitemid 30185469)
18. De Luca L., Colucci W. S., Nieminen M. S., Massie B. M., Gheorghiade M., Evidence-based use of levosimendan in different clinical settings European Heart Journal 2006 27 16 1908 1920 (Pubitemid 44297362)
19. Lilleberg J., Laine M., Palkama T., Kivikko M., Pohjanjousi P., Kupari M., Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure European Journal of Heart Failure 2007 9 1 75 82 (Pubitemid 46074480)
20. Cleland J. G. F., Freemantle N., Coletta A. P., Clark A. L., Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE European Journal of Heart Failure 2006 8 1 105 110 (Pubitemid 43012109)
21. Varro A., Papp J. G., Classification of positive inotropic actions based on electrophysiologic characteristics: where should calcium sensitizers be placed? Journal of Cardiovascular Pharmacology 1995 26 1 S32 S44